| Autor: |
Masferrer JL; Department of Inflammatory Diseases Research G.D. Searle T3G, St. Louis, USA, and Analytical Sciences Center, Monsanto Corporate Research., Zweifel BS, Colburn SM, Ornberg RL, Salvemini D, Isakson P, Seibert K |
| Jazyk: |
angličtina |
| Zdroj: |
American journal of therapeutics [Am J Ther] 1995 Sep; Vol. 2 (9), pp. 607-610. |
| DOI: |
10.1097/00045391-199509000-00005 |
| Abstrakt: |
Prostaglandins (PGs) can be synthetized via two isoforms of cyclooxygenase (COX). COX-1 is constitutively expressed in normal tissues, and its activity represent the normal physiological output of PGs. In inflammatory states, the newly discovered COX-2 is rapidly induced, and its activity accounts for the large amounts of PGs seen in inflammation. The commercially available nonsteroidal anti-inflammatory drugs (NSAIDs) are nonselective inhibitors of both COX isoforms; therefore, they provide anti-inflammatory activity as well as side effects associated with COX-1 inhibition. Selective inhibition of COX-2 expression explains at least in part the potent anti-inflammatory activity of steroids. Anti-inflammatory activity of newly developed COX-2 inhibitors, such as NS-398 or SC-58125, suggest a new approach of inflammatory diseases with more efficacious NSAIDs essentially devoid of side effects such as stomach ulcers. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
